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Abstract: MRCKα is a ubiquitously expressed serine/threonine kinase involved in cell contraction
and F-actin turnover, which is highly amplified in human breast cancer and part of a gene expression
signature for bad prognosis. Nothing is known about the in vivo function of MRCKα. To explore
MRCKα function in development and in breast cancer, we generated mice lacking a functional
MRCKα gene. Mice were born close to the Mendelian ratio and showed no obvious phenotype
including a normal mammary gland formation. Assessing breast cancer development using the
transgenic MMTV-PyMT mouse model, loss of MRCKα did not affect tumor onset, tumor growth
and metastasis formation. Deleting MRCKα and its related family member MRCKβ in two triple-
negative breast cancer cell lines resulted in reduced invasion of MDA-MB-231 cells, but did not affect
migration of 4T1 cells. Further genomic analysis of human breast cancers revealed that MRCKα
is frequently co-amplified with the oncogenes ARID4B and AKT3 which might contribute to the
prognostic value of MRCKα expression. Collectively, these data suggest that MRCKα might be a
prognostic marker for breast cancer, but probably of limited functional importance.
Keywords: MRCK; breast cancer; invasion
1. Introduction
Rho GTPases are small GTPases regulating the organization of the actin cytoskeleton
and cell migration, but also differentiation, proliferation and other cellular processes [1].
They exert their function by binding and activating in their GTP bound form to effector
molecules which then mediate the biological effects. The myotonic dystrophy kinase-
related Cdc42-binding kinase α (MRCKα; gene name CDC42BPA) is an effector of the
ubiquitously expressed Rho GTPases Cdc42 and possibly Rac1 [2,3]. Binding of Cdc42 to
MRCKα leads to autophosphorylation of MRCKα at S1003, which correlates with kinase
activity [4]. Kinase activity is furthermore regulated by diacylglycerol binding to the
centrally located C1 domain [5]. The MRCKα kinase domain is about 80% homologous
to the kinase domain of MRCKβ [6–8], and furthermore similar to the kinase domain of
ROCK1/2, two closely related Rho effectors. This is believed to result in a shared set of
substrates between MRCKα, MRCKβ and ROCK1/2, including the regulatory subunits
of the myosin light chain phosphatase (MYPT1) and of myosin II (MLC2) and the LIM
kinases 1 and 2 [9]. Since phosphorylation of MYPT1 and MLC2 promotes cell contraction,
while phosphorylation of the LIM kinases mediates inactivation of the F-actin severing
cofilin, MRCKα is proposed to play an important role in the regulation of cell migration in
collaboration with MRCKβ, ROCK1 and ROCK2.
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Indeed, several studies support an important role for MRCKα in cancer cell migration.
In elongated MDA-MB-231 breast cancer cells, contraction and invasion into collagen or
matrigel is jointly regulated by MRCKα, MRCKβ, ROCK1 and ROCK2 [9,10]. Inhibition of
either MRCKα/β or ROCK1/2 alone had only a partial effect. Invasion of the squamous
cell carcinoma line SSC12 in an organotypic skin culture model, on the other hand, was
largely dependent on MRCKα and MRCKβ function [11]. In 2D migration, inhibition
of both MRCKs by BDP9066 significantly reduced migration speed without affecting
directionality [4]. However, MRCKs and ROCKs do not appear to always have overlapping
effects. In neurite outgrowth assays in vitro, MRCKα is required for outgrowth, while
ROCK1 promotes retraction [12]. Additionally, MRCKα/β are responsible for promoting
SCC cell invasion through the matrix, whilst ROCK1/2 signaling contributes only in the
leading fibroblasts to migration [11].
Little is known about the in vivo function of MRCKα during development and in
disease, but several studies indicated a role for MRCKα in tumor formation. In DMBA/TPA
induced skin tumor in mice, a strongly increased expression of MRCKα and MRCKβ was
observed [4]. Treatment with the MRCK inhibitor BDP9066 reduced the total tumor volume,
but not the frequency of the papilloma, suggesting a role for MRCKs in tumor growth. This
notion was supported by antiproliferative effects of BDP9066 on many cancer cell lines
in vitro. In human breast cancer, MRCKα copy number was reported to be increased in
64% of 852 breast cancer samples at the Wellcome Trust Sanger Institute Cancer Genome
Project [8]. Moreover, in a gene expression study of breast cancer patients, MRCKα, alias
PK428, was identified as part of a profile of 70 genes predicting short interval to metastasis
formation and poor prognosis [13]. These data suggest a potential role for MRCKα in
breast cancer, although no validation analysis has been carried out.
To directly address the role of MRCKα in malignant breast cancer, we generated mice
with a constitutive knockout of MRCKα using CRISPR genome editing and investigated
their development and, by crossing with MMTV-PyMT mice, the formation of breast
cancer. In addition, we tested redundancy of MRCKα and MRCKβ in breast cancer cell
lines in vitro. Our data reveal a dispensable role in MMTV-PyMT breast cancer model
and cell type specific roles in 3D collagen gel invasion of breast cancer cells. In addition,
we uncovered a co-amplification of MRCKα with two other known oncogenes in human
cancers, which might contribute to the worse prognosis of breast cancer patients with
amplified MCRCKα.
2. Materials and Methods
2.1. Generation of MRCKα Ko Mice and Mammary Cancer Model
MRCKα KO mice were generated by the Transgenic Mouse Core Facility, University
of Copenhagen, by direct injection of Cas9 mRNA and a guide RNA targeting exon 1 of
mouse MRCKα (5′–TGTCCGGAGAAGTGCGTTTG AGG) to zygotes. The PAM sequence
is underlined. Injected zygotes were embryo-transferred and mice born were genotyped
by sequencing of the amplified target region. KO mice investigated in this study were
genotyped with following a touchdown PCR protocol. The PCR cycling conditions were:
95 ◦C for 3 min, a touchdown phase consisting of 10 cycles of 95 ◦C for 30 s, a temperature
ramp from 63 ◦C to 58 ◦C for 45 s at 0.5 ◦C per cycle, 72 ◦C for 1 min and then a second
phase consisting of 25 cycles of 95 ◦C for 30 s, 58 ◦C for 45 s, 72 ◦C for 1 min and a final
extension step of 72 ◦C for 10 min.
For the spontaneous mammary tumour model, MMTV-PyMT MRCKα HET male
mice were crossed with HET female. MMTV-PyMT HET and MMTV-PyMT KO mice were
monitored daily and sacrificed once the total tumour volume reached 1000 mm3. All animal
experiments were carried out following national and European animal welfare regulations
and were approved by the Danish Board for Animal Experiments (2016-15-0201-00946).
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2.2. Quantification of Lung Micrometastasis
The number of micrometastases was counted manually on fixed lungs by Hematoxylin-
Eosin staining of 5 µm paraffin sections of the left lung. Three random sections at least
100 µm apart in distance in the tissue were used for quantification per sample.
2.3. Primary Mammary Tumor Organoids
Primary tumor organoids were isolated from mammary tumors as previously de-
scribed [14,15]. Briefly, mammary tumors were harvested from mice reaching end-point,
minced with a scalpel and digested for 1 h at 37 ◦C in a collagenase solution (DMEM/F12
containing 2 mg/mL collagenase, 2 mg/mL trypsin, 5% FBS, 5 µg/mL insulin and
50 µg/mL gentamicin). The suspension was centrifuged at 500× g for 10 min and the
supernatant was carefully removed. The pellet was resuspended in warm DMEM/F12
media containing 1 U/µL DNAse I and incubated for 5 min. The suspension was then
filtered through a 100 µm cell strainer and then pulse-centrifuged at 500× g to remove the
supernatant which contains fibroblasts. The pulse-centrifuging step was repeated a total of
4 times, or until the supernatant runs clear. The final pellet was resuspended in organoid
culture media (DMEM/F12 containing 1% penicillin/streptomycin, 1% insulin-transferrin
selenium and 2.5 nM human fibroblast growth factor basic) prior to being embedded in
collagen I matrix.
2.4. Carmine Alum and Nissl Staining
For mammary gland branching analysis, 4th inguinal mammary fat pads were pre-
pared as whole mount samples and carmine alum staining was performed according to
the protocol as previously described [16]. For the analysis of brain sections, sagittal brain
sections at 5 µm thickness were stained in 0.5% cresyl violet solution containing 3% glacial
acetic acid, according to standard procedures for Nissl staining.
2.5. Cell Lines
Human MDA-MB-231 and murine 4T1 cells (both obtained by J. Erler, BRIC, University
of Copenhagen). Immortalized mouse cancer associated fibroblasts were isolated from
wildtype MMTV-PyMT tumors and immortalized by retroviral transduction of HPV-E6
29 [17]. CAFs were cultured in low- glucose DMEM containing 10% fetal bovine serum,
1% penicillin/streptomycin (Thermo Fisher Scientific, Lillerød, Denmark and 1% Insulin-
Transferrin-Selenium (ITS-G) from Gibco. Cells were treated as indicated with 10 µM
Y-27632 or 1 µM latrunculin (both Tocris, Abingdon, UK). All cell cultures were maintained
at 37 ◦C, 5% CO2.
2.6. Lentiviral Transduction
Single guide RNAs (sgRNA) targeting human MRCKα and MRCKβ coding regions
were designed and cloned into the lentiviral vector lentiCRISPRv2 (GeCKO; Addgene,
Watertown, MA, USA) according to manufacturer’s instructions. The oligonucleotide
sequences corresponding to the human sgRNAs used were:
hMRCKa guide 1: F: 5′ CACCGGCGGGCCCGCTCAGACCAA, R:5′ AAACTTGGTCT-
GAGCGGGCCCGCC
hMRCKa guide 2 F: 5′ CACCGGAAGTGCGTTTGAGGCAGT, R:5′ AAACACTGCCT-
CAAACGCACTTCC
hMRCKb guide 1 F: 5′ CACCGGGCGGCACCATGTCGGCCA, R:5′ AAACTGGCCGA-
CATGGTGCCGCCC
hMRCKb guide 2 F: 5′ CACCAGGGCGCTCTCGTTGCGCCA, R:5′ AAACTGGCGCAAC-
GAGAGCGCCCT
The oligonucleotide sequences corresponding to the mouse sgRNAs used were:
mMRCKa guide 1: F: 5′ CACCGGGTCCGGAGAAGTGCGTTTG, R:5′ AAACCAAACG-
CACTTCTCCGGACCC
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mMRCKa guide 2 F: 5′ CACCGGAAGTGCGTTTGAGGCAGT, R:5′ AAACACTGCCT-
CAAACGCACTTCC
hMRCKb guide 1 F: 5′ CACCGGGGGCGGAGTTCCTCGAGTG, R:5′ AAACCACTCGAG-
GAACTCCGCCCCC
Since no obvious differences were observed between ko cells generated with guide 1
or guide 2, results obtained with different guides for the same gene were pooled.
To produce viral particles, HEK293T cells were transfected with lentiviral vectors
following standard procedures and viral supernatant was used to infect target cell lines.
Selection was done using either puromycin (1–2 µg/mL) or blasticidin (8–10 µg/mL), 48 h
post-transduction. An empty vector was transduced into cells as control.
2.7. Cell Adhesion
A 96-well tissue culture plate was coated for 1 h at room temperature using type I
rat tail collagen serially diluted in PBS starting from 10 µg/mL to 0.00064 µg/mL. After
coating, the plate was washed three times with PBS and then blocked in 1% BSA for 1 h.
The plate was washed again for three times in PBS and cells are then seeded in serum-
free media at a density of 2 × 104 cells per well and allowed to adhere. After 30 min of
incubation at 37 ◦C, the plate was washed one time with PBS and the cells were given
complete media and incubated at 37 ◦C for 3 h. The cells were fixed in 4% PFA for 20 min
at room temperature and then stained in crystal violet diluted in 20% methanol for 15 min.
After washing in PBS and then water, the plate was dried and the stain was extracted by
1% SDS in PBS. The extracted dye was transferred to a 96 well plate and absorbance at
560 nm was then read from the plate.
2.8. Cell Proliferation Assay
Cells were seeded at a density of 7 × 103 per well in a 12 well plate format. After
overnight incubation, the cells were placed in the Incucyte system for live cell imaging and
automated quantification. An image was taken every 2 h, for a total of 48 h.
2.9. F and G Actin Fractionation
For fractionation of the F and G actin cells were lysed in actin stabilization lysis
buffer (50 mM PIPES, 50 mM NaCl, 5 mM MgCl2, 5 mM EGTA, 2 mM ATP, 5% glycerol,
0.1% Nonidet P-40, 0.1% Triton X-100, 0.1% Tween 20, 0.1% β-mercaptoethanol, protease
inhibitors and phosphatase inhibitors) for 10 min at 37 ◦C. Cell debris were removed by
centrifugation at 300× g and protein concentration of the supernatant was determined.
After equilibrating the protein concentration of the samples using the lysis buffer, an aliquot
of the lysate (10% of total volume) was stored as total protein input, while the remainder
was subjected to ultracentrifugation at 100,000× g for 1 h at 37 ◦C. After centrifugation,
the supernatant containing G actin was carefully transferred to a new tube and stored,
while the pellet containing F actin was resuspended in cold lysis buffer containing 1 µM
cytochalasin D and incubated on ice for 45 min to dissolve the fibers into monomers. All
fractions were then boiled in Laemmli buffer and prepared for Western blotting.
2.10. Western Blot Analysis
Tissue fragments and cultured cells were lysed with Laemmli buffer. Lysates were
separated by a 10% SDS-PAGE and Western blotting was carried out following standard
protocols. For detection, the following primary antibodies were used: MRCKα (#374568),
MRCKβ (#374597), GAPDH (#25778; all SantaCruz Biotechnology, Dallas, TX, USA), pMLC
(#3674), pCofilin (#3311; all Cell Signaling, Danvers, MA, USA), β actin (#AB6276, Abcam,
Cambridge, MA, USA). For detection, appropriate HRP coupled secondary antibodies were
used: horse-anti-mouse IgG (#VECTPI2000), goat-anti-rabbit IgG (#VECTPI1000, all Vector
Laboratories, Burlingame, CA, USA). LuminataTM Western HRP Chemiluminescence
Substrates detection reagent (Milipore, Hellerup, Denmark) was used for chemilumines-
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cence, which was then detected with Medical X-ray film (AGFA, Birkerød, Denmark). The
intensity of the bands was quantified using ImageJ software.
2.11. D Spheroid Invasion Assay
Spheroids were generated from aggregated cells, either homogenously or heteroge-
neously in combination with CAF [17]. Briefly, 500 cancer cells (with or without 500 CAFs)
were seeded into 96 well round bottom plates containing 20% methylcellulose in serum-free
DMEM. After overnight incubation at 37 ◦C and 5% CO2, the aggregated spheroids were
embedded in 2 mg/mL collagen I (Corning, Glendale, AZ, USA) in 12-well plates at ap-
proximately 10 spheroids per well. After polymerization, the collagen matrix was overlaid
with 500 µL of DMEM containing 2% FBS and, when indicated, 10 µg/mL Y-27632 (Sigma
Aldrich, St. Louis, MO, USA). The spheroids were imaged immediately after overlaying
with media to obtain the initial area of the core spheroid and again after 24 h incubation.
Phase contrast images were captured using an Olympus CellSens imaging software.
2.12. Spheroid Image Quantification
For quantification, images were analyzed using Fiji/ImageJ [18,19]. Spheroid area
measurements were determined semi-automatically using a custom macro on ImageJ. First,
images were smoothed by applying a Gaussian blur filter with a sigma of 2. Next, the
spheroid was outlined by manual thresholding. Gaps in the spheroids were filled with
the Fill Hole command and the total area of the spheroid was then measured. The area of
the spheroid imaged at 24 h post-embedding was subtracted from that obtained at 0 h, to
obtain the final area of the invasion zone.
2.13. Time-Lapse Microscopy
5 × 103 MDA-MB-231 cells stably expressing a LifeACT-GFP plasmid (Addgene, Wa-
tertown, MA, USA) were seeded in 8-well chambered glass slides. 24 h post-incubation,
the cells were then imaged by time-lapsed microscopy on a DeltaVision suite Olympus
microscope. Images were captured every 5 s for a total of 10 min, under a 40× magnifi-
cation using immersion oil. Kymographs were generated as described previously using
ImageJ [20]. Briefly, a line was first drawn from the middle of the cell perpendicularly
towards the migrating front of cells. Then, the Reslice function was used to generate the
kymograph. A new line was again drawn along each actin protrusion on the kymograph
and the enclosed triangle, of which each dimension corresponds to the protrusion length
(P), persistence (S) and protrusion rate (P/S), were then measured in pixel units. All lines
are indicated in the corresponding figure.
2.14. RNA-Sequencing and Data Analysis
Total RNA was isolated from vector control, MRCKα KO, MRCKβ KO or DKO
MDA-MB-231 cells using standard RNA purification kit (Sigma-Aldrich, St. Louis, MO,
USA). For DKO samples, 2 different sets were generated using the guide 1 or the guide
2 gRNAs for hMRCKα or hMRCKβ. Two sets of control samples were obtained from
two separate transductions of the vector plasmid. RNA sequencing was performed by
the Beijing Genomics Institute (BGI). Sequencing depth was at least 10 M clean reads per
sample via SE50. To compare the differential gene expression, the FPKM values obtained
from the analysis performed by BGI were used. For the control and DKO samples, FPKM
values from both transductions (vector) or both gRNA sets (DKO) were first compared and
FPKM of genes that differed by more than 2-fold were excluded from subsequent analysis.
An average is obtained from the remaining genes. Log2 fold-change was then calculated
for the MRCKα KO, MRCKα KO and DKO samples against vector control. An arbitrary
log2 fold change of 1 (and −1) was used as threshold for differential expression.
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2.15. Statistics
Data are presented as means with error bars representing standard error of the mean.
Statistical significance was determined by the two-tailed Student’s t-test, if not indicated
otherwise. For all statistical analyses, p values are denoted as: *** p < 0.001, ** p < 0.01 and
* p < 0.05.
3. Results
3.1. MRCKα Expression Correlates with Survival in Triple-Negative Breast Cancer
MRCKα expression has been reported to be increased in breast cancer. Indeed, around
11% of the breast cancers of the TCGA breast cancer data set (cbioportal.org) [21,22] showed
genetic alterations of the MRCKα gene, most of them amplifications (Figure 1a). The closely
related MRCKβ gene was only altered in 2.6%, including both amplifications and homozy-
gous deletions (Figure 1a). Further investigating the patients with amplifications of the
MRCKα gene, we observed a trend towards reduced progression free survival, suggesting
that amplification of the MRCKα gene might be disease relevant (p = 0.087; Figure 1b).
Amplifications of the MRCKα gene were observed in Basal, Her2+, Luminal A, Luminal B
and Normal breast cancers, but were enriched in the Basal subgroup (Figure 1c). Average
expression of MRCKα in the amplified subset was increased by about 21% compared to
the non-amplified subset (p = 0.015). In contrast, increased expression of MRCKβ showed
no obvious effect on breast cancer survival and cancers with high expression of MRCKβ
were strongly depleted in the Basal subset (Supplementary Figure S1). These data suggest
that MRCKα expression might be of relevance for breast cancer formation and progression
in all subtypes, but probably most in Basal Cancer.
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Figure 1. MRCKα gene is amplified in breast cancer. (a) Genetic alterations of the MRCKα and MRCKβ genes in breast
cancer. (b) Progression free survival of breast cancer patients with amplified and non-amplified MRCKα gene (p = 0.087).
(c) Breast cancer subtype distribution of patients with amplified (amp) and not amplified (not amp) MRCKα gene. All
graphs were generated in cBioPortal.org using the TCGA PanCancer Atlas data set for invasive breast carcinoma (accessed
on 20 March 2021).
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3.2. MRCKα Ko Mice Do Not Show an Obvious Phenotype
To analyze the requirement of MRCKα for breast cancer, we first generated mice lack-
ing a functional MRCKα gene (Cdc42bpa) using CRISPR genome editing. Several MRCKα
mutant mouse lines were generated and the p.Leu7fs*35 line (KO) in which an extra “T”
was introduced into the leucine 7 codon (Figure 2a) was chosen for further analysis.
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Figure 2. MRCKα ko mice show no obvious phenotype. (a) Genotype profile of ko mice showing the
p.Leu7fs*35 mutation. * in icates the inserted nucleotide in the chromato ram. (b) Representative
results from genotyping PCR using primers targeting the utation specifically. (c) Body weight
measurements of post-weaning female wild-type, heterozygous and ko mice. (d) Representative
images of wild-type and ko mice. (e) Mendelian ratio of the observed and expected frequencies of
wild-type, heterozygous and ko mice in Het × Het mating (n = 82) and Het × KO (n = 58) mating
pairs. (f) Immunoblot analysis of MRCKα and MRCKβ expression in wild-type and ko mice.
Homozygous KO mice developed without obvious defects and showed normal size
and body weight (Figure 2b–d). Cage behavior (explorative activity, body posture, culling)
was indistinguishable from control litter mates (wildtype, heterozygous) and both male
and female ko mice were fertile. Crosses of heterozygous mice (Het), showed a slight
reduction of KO mice compared to the expected level (Figure 2e). However, checking
embryonic litters at different time points before birth no evidence for prenatal lethality
or morphological defects could be found (data not shown). Moreover, crosses of KO and
Het were born roughly at the Mendelian ratio, giving no indication for partial embryonic
lethality (Figure 2e).
To confirm the loss of MRCKα on protein level, lysates of brain, mammary gland,
liver and skin were analyzed by Western blotting. WT mice showed that, in addition to
the expected isoform of about 190 kD corresponding to the full-length MRCKα, smaller
isoforms of about 130 kD were detectable. In brain, larger and smaller isoforms were
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equally expressed, while in the other tissues the smaller isoform was dominant (Figure 2f).
Both isoforms were not detectable in KO mice, indicating efficient gene deletion and
specificity of the antibody. The closely related MRCKβ was also expressed in different
isoforms in all tissues tested. In addition, liver, the high molecular weight isoform was
more prevalent (Figure 2f). Loss of MRCKα did not result in increased protein levels of
MRCKβ in the tissues investigated.
Since MRCKα was highly expressed in brain and in mammary gland we assessed
both tissues for histological changes in the KO mice. However, Nissl staining of sagittal
brain sections (Figure 3a) revealed no obvious alterations. Histological analysis of the
mammary gland by hematoxylin/eosin staining indicated normal ducts surrounded by a
thin layer of connective tissue in both WT and KO (Figure 3b). Moreover, whole mount
staining by carmine alum indicated normal branching morphogenesis of the mammary
ducts in MRCKα KO mice (Figure 3c,d).




Figure 3. Mrckα knockout does not affect brain and mammary gland development. (a) Representative Nissl staining of 
sagittal brain sections from adult wild-type and ko mice. Scale bars: 2.5 mm (b) Representative H&E staining of the 4th 
inguinal mammary glands from 7-weeks old virgin female wild-type and KO mice. Scale bars: 100 μm. (c) Representative 
carmine alum-stained mammary gland whole mounts. LN denotes the inguinal lymph node. A black box was drawn to 
indicate the area of magnification of the image, as shown in (d). 
Figure 3. Mrckα knockout does not affect brain and mammary gl d dev lopment. (a) Representative
Nissl s ining of sagittal brai section from dult wild-type and ko mice. Scale bars: 2.5 mm.
(b) Representative H&E staining of the 4th inguinal mammary glands from 7-weeks old virgin female
wild-type and KO mice. Scale bars: 100 µm. (c) Representative carmine alum-stained mammary
gland whole mounts. LN denotes the inguinal lymph node. A black box was drawn to indicate the
area of magnification of the image, as shown in (d).
These data reveal that MRCKα is not required for development. Importantly, the
normal development of the mammary gland and the normal overall phenotype provides
an excellent basis for the analysis of the role of MRCKα in breast cancer development, since
a potential tumor phenotype will not be affected by a developmental phenotype.
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3.3. MRCKα Is Not Essential for Tumorigenesis or Metastasis in the Mmtv-Pymt Breast Cancer Model
To investigate the role of MRCKα in breast cancer in an in vivo model, we crossed the
MRCKα KO mice with MMTV-PyMT mice, which spontaneously develop invasive ductal
breast carcinoma with metastases in the lung [23].
Surprisingly, loss of MRCKα did not affect the tumor onset, tumor-free survival and
tumor volume (Figure 4a–c). Histological analysis of tumors in KO and Het control mice
indicated adenocarcinoma characterized by increased size of nuclei, nuclear pleomorphy,
prominent nucleoli and areas of necrosis in more advanced carcinoma (Figure 4d). Occa-
sional infiltration of mononuclear cells and desmoplasia were observed. Tumors appeared
relatively solid without single cells or small groups of cells detached from the main tumor.
Western blot analysis of tumors confirmed the lack of MRCKα and showed no clear com-
pensatory upregulation of MRCKβ (Supplementary Figure S2a). In one of 6 KO tumors,
MRCKα expression was even decreased. Frequency and histology of lung metastases was
similar in Het and KO mice (Figure 4e,f).
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in MMTV-PyMT mice. (a) Weeks tumour-free (b) survival analysis (p = 0.8243, log-rank test) and 
(c) tumor volume at end-point of MMTV-PyMT heterozygous (Het) vs. KO mice (n ≥ 10/10). (d) 
Representative H&E staining of MMTV-PyMT heterozygous or Mrckα KO mice primary tumours 
showing extensive necrosis (black arrows). Images on the right represent the same images at 
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To identify qualitative changes in the invasion process, we monitored breast cancer
invasion in tumor organoids embedded in collagen. Collective cell migration of cancer
cells into the collagen gel was detected in both Het and KO cancers without any apparent
alterations in KO tumor organoids (Supplementary Figure S1b). These data suggest that
MRCKα is not essential for breast cancer development, progression and lung metastasis in
the MMTV-PyMT model.
3.4. MRCKα Is Important for 3D Collagen Gel Invasion of MDA-MB-231 Breast Cancer Cells
The unaltered breast cancer development in MRCKα ko mice could be related to
functional redundancy of MRCKα with MRCKβ. To investigate this possibility, we deleted
the genes for MRCKα and MRCKβ individually or alone in two breast cancer cell lines.
Since it was shown earlier that siRNA mediated knockdown of MRCKα and MRCKβ
together reduces matrigel invasion of the triple-negative breast cancer cell line MDA-MB-
231 [9], we chose this cell line for the experiments.
MDA-MB-231 breast cancer cells lacking MRCKα, MRCKβ, or both (DKO) were
established by lentiviral CRISPR genome editing and selection for stably transduced cells.
As a control, MDA-MB-231 cells were transduced with the empty vector. Control MDA-
MB-231 cells expressed primarily the high molecular weight isoforms of MRCKα and
MRCKβ (Figure 5a). Even without clone picking, the efficiency of gene deletion was very
high as tested on protein level (Figure 5a–c). Interestingly, KO of MRCKα resulted in a
slight but significant increase in MRCKβ expression. On the other hand, loss of MRCKβ
did not affect MRCKα protein levels to a significant extent.
Next, invasion of spheroid aggregates of the different MDA-MB-231 breast cancer cell
lines mixed with CAFs into 3D collagen gels was assessed. Initially, all spheroids were
relatively compact and of similar diameter, although some cells were already detached
from the main cell mass at 0 h (Figure 5d; Supplementary Videos S1 and S2). Reproducibly,
the number of detached cells at 0 h was lower for DKO than for WT, suggesting reduced
invasiveness (Supplementary Videos S1 and S2). For the quantification, only the differences
between 24 h and 0 h was taken into consideration (Figure 5d).
After 24 h, MRCKα KO spheroids showed significantly less invasion than control
cells (Figure 5e,f). DKO spheroids also showed defective 3D migration, while MRCKβ KO
spheroids were indistinguishable from controls. Movies demonstrated that both control
and DKO cells invaded the collagen gel mostly in a rounded and less frequently in an
elongated form (Supplementary Videos S1 and S2).
These data indicate a role for MRCKα in the collagen invasion of MDA-MB-231 breast
cancer cells, but not for MRCKβ.
3.5. Subtle Cellular and Biochemical Alterations in Mutant MDA-MB-231 Cells Cultured in 2D
To identify cellular and biochemical alterations of the MDA-MB-231 cells with muta-
tions in MRCK genes, we investigated the breast cancer cells in 2D culture. MRCK single
and double KO cells were morphologically similar to control MDA-MB-231, with a slightly
elongated cell shape (Figure 6a). Assessing proliferation in a confluency assay, KO lines and
control cells showed a similar growth rate (Figure 6b). Furthermore, adhesion to collagen
was identical in all cells (Figure 6c), suggesting that integrin mediated collagen binding is
not changed by loss of MRCK.
To study dynamic changes in F-actin formation and protrusions at the plasma mem-
brane, we transfected the cells with the fluorescent F-actin marker LifeAct and monitored
F-actin by time lapse fluorescence microscopy. In randomly chosen sections through lamel-
lipodial regions, distance, persistence and rate of protrusions was measured by kymograph
analysis (Figure 6d–f). Distance of protrusions was slightly higher in MRCKα KO and
lower in DKO, suggesting that loss of MRCKα and MRCKβ results in subtle changes in
actin cytoskeleton dynamics (Figure 6g–i).
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Figure 6. MRCK KO has a modest effect on F-actin polymerization. (a) Representative phase contrast
images showing the morphologies of control, MRCKα KO, MRCKβ KO, or DKO MDA-MB-231
cells (b) Proliferation rate of MRCKα KO, MRCKβ KO and DKO MDA-MB-231 cells as measured
by relative confluency over time. (c) Relative adhesion of MRCKα KO, MRCKβ KO and DKO
MDA-MB-231 cells to increasing concentration o type I collagen. Data is obtained for 3 biological
replicates. (d–i) Kym graph analysis of actin protrusi n distance, rate and persistence in MRCK
KO cells (d) Representative still image of an MDA-MB-231 cell expressing LifeAct-GFP used in live
imaging. A white line was drawn perpendicular to the cell body to indicate the position where
kymograph was obtained. (e) Example of a kymograph generated using the reslice function on
ImageJ program, showing the distance and time in the y and x axis, respectively. A white box is used
to highlight an actin protrusion and the image magnified in (f). (f) Example of a measurement of
actin protrusion distance, D, persistence, P and protrusion rate, R. (g) Kymograph measurements
obtained for protrusion distance, ** p ≤ 0.01 (h) persistence and (i) protrusion rate.
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Earlier, MRCKα and MRCKβ were shown to regulate together with ROCK the phos-
phorylation of cofilin and myosin light chain (MLC), corresponding to increased F-actin
formation and increased cell contraction. Unexpectedly, in our MDA-MB-231 cells neither
in MRCKα KO nor in MRCKβ KO a decrease in pMLC, pCofilin, or F-actin was detectable
(Figure 7a–e). They rather appeared to be increased in MRCKα KO MDA-MB-231 cells,
although the differences were not significant. DKO cells showed slightly reduced pMLC
compared to vector transfected controls.
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tive immunoblot showing myosin light chain (pMLC) and phospho-cofilin in MDA-MB-231 cells with MRCKα KO, 
MRCKβ KO, or DKO. (b,c) Quantitation of indicated proteins from lysates obtained from the knockout cells (n:6/6/6/6; 
mean ± SEM, one-way ANOVA; * p ≤ 0.05). (d) Representative immunoblot showing levels of F-actin and G-actin in control, 
MRCKα KO, MRCKβ KO and DKO MDA-MB-231 cells. As a control, cells were also treated with 1 μM latrunculin A (Lat 
A) for 15 min. (e) Quantification of F/G-actin ratio (n: 6/6/6/6; mean ± SEM, not significant with one-way ANOVA, * p ≤ 
0.05 with two-tailed t-test for Vector vs. MRCKa KO). 
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Figure 7. MRCK KO does not effectively reduce myosin and cofilin phosphorylation in MDA-MB-
231 cells (a) Representative immunoblot showing myosin light chain (pMLC) and phospho-cofilin
in DA-MB-231 cells with MRCKα KO, MRCKβ KO, r DKO. (b,c) Quantitation of indicated
proteins from lysates obtained from the knockout cells (n: 6/6/6/6; mean ± SEM, one-way ANOVA;
* p ≤ 0.05). (d) Representative immunoblot showing levels of F-actin and G-actin in control, MRCKα
KO, MRCKβ KO and DKO MDA-MB-231 cells. As a control, cells were also treated with 1 µM
latrunculin A (Lat A) for 15 min. (e) Quantificati n of F/G-actin r tio (n: 6/6/6/6; mean ± SEM, not
significant with one-way ANOVA, * p ≤ 0.05 with two-tailed t-test for Vector vs. MRCKa KO).
We then tested for differential gene expression by RNA sequencing, excluding poorly
expressed genes. Functional annotation of the differentially regulated genes by DAVID
suggested a coordinated regulation of immune response related genes in the DKO and the
MRCKα KO cells, with no obvious indication of any alterations in pathways related to cell
migration (Supplementary Figures S3–S5). The lists of top up- and down-regulated genes
in the MRCK KO cells can be found as Supplementary Tables S1–S6). Within the lists, none
of the genes altered more than 2-fold was obviously related to actin cytoskeletal regulation
or cell migration, besides the actin nucleator LMOD1 [24], which was upregulated in
MRCKβ KO cells, but neither in MRCKα KO nor in DKO cells. This suggests that MRCKα
and MRCKβ regulate cell migration mainly at posttranscriptional level. Taken together,
MRCKα KO and DKO cells display small changes in 2D culture compared to control cells.
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3.6. Collective 3D Invasion of 4T1 Breast Cancer Is Not Dependent on MRCKα
MDA-MB-231 cells invade collagen gels mostly as single cells, while the tumor
organoids of MRCKα KO and control breast cancers only showed collective migration
(Supplementary Figure S1b). To test the function of MRCKα and MRCKβ in 3D collagen gel
invasion assays also with triple-negative breast cancer cells showing collective migration,
we performed additional experiments with murine 4T1 cells. CRISPR genome editing
resulted in efficient deletion of MRCKα and MRCKβ protein as tested by Western blot
(Figure 8a). As was the case for MDA-MB-231 cells, MRCKα KO cells have increased
MRCKβ expression, although the reverse was not consistently observed (Supplementary
Figure S6a,b). Control, KO and DKO cells showed similar morphology and were both
growing in colonies, suggesting strong cell-cell interactions (Figure 8b). In 3D collagen
gel invasion assays, 4T1 cells displayed collective migration similar to the organoids iso-
lated form the MMTV-PyMT mice (Figure 8c,d). However, neither deletion of MRCKα or
MRCKβ or both reduced the invasion significantly.




Figure 8. MRCKα and MRCKβ are dispensable in 4T1 cells matrix invasion. (a) Representative immunoblot showing suc-
cessful knockout of MRCKα and MRCKβ in 4T1 cells. DKO was achieved by using one of two different CRISPR gRNAs 
for MRCKα (“MRCKα 1 + 2”) and one gRNA for MRCKβ (b) Representative phase contrast images of control, MRCKα, 
MRCKβ and DKO 4T1 cell morphologies in the presence and absence of Y-27632 (10 μM). (c) 3D matrix invasion of MRCK 
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breast cancers of the TCGA PanCancer dataset whether other amplified oncogenes are 
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Figure 8. MRCKα and MRCKβ are dispensable in 4T1 cells matrix invasion. (a) Representative
immunoblot showing successful knockout of MRCKα and MRCKβ in 4T1 cells. DKO was achieved
by using one of two different CRISPR gRNAs for MRCKα (“MRCKα 1 + 2”) and one gRNA for
MR (b) Representative pha e cont a t images of ontrol, MRCKα, MRCKβ a d DKO 4T1 cell
morphologies in the presence and absence of Y-27632 (10 µM). (c) 3D matrix invasion of MRCK KO
4T1 spheroids in type I collagen, in the presence and absence of Y-27632 (10 µM). Black boxes highlight
the invasi n front of the control spheroids, as s own magnified in the right panel. (d) Quantification
of the area of invasion of the 4T1 spheroids from (c) relative to 24 h control (n: 3; mean ± SEM,
one-way ANOVA; * p ≤ 0.05, *** p ≤ 0.001). (e) Representative immunoblot and (f,g) quantification
of the expression of the indicated proteins. (n: 5; mean ± SEM, one-way ANOVA).
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Previously, it had been shown that inhibition of ROCK1 and ROCK2, in addition to
MRCKα and MRCKβ strongly impaired migration of cancer cells [9,10]. We therefore
repeated the collagen invasion assay in the presence of Y-27632, which efficiently inhibits
ROCK1 and ROCK2. Unexpectedly, however, Y-27632 increased the collagen invasion
of 4T1 cells (Figure 8c,d). Deletion of MRCKα and even more of MRCKβ blocked this
increased invasion. DKO cells showed a reduced invasion when ROCK was inhibited.
In the presence of Y-27632, cell-cell borders became clearly visible in all 4T1 lines in 3D,
suggesting altered cell-cell contacts (Figure 8c). Still, cells appeared not to migrate as
individual cells in contrast to MDA-MB-231 (Figure 5). In 2D, Y-27632 treated cells grew
less in colonies and displayed thin and long plasma membrane protrusions (Figure 8b).
Phosphorylated MLC (pMLC) and pCofilin were not significantly affected by the loss of
MRCKα, MRCKβ, or both (Figure 8e–g). These data suggest that inhibition of ROCK
signaling promotes invasion of 4T1 breast cancer cells in an MRCK dependent manner, but
a dispensable role for MRCKα and MRCKβ in 4T1 cell for collective cell migration in 3D.
3.7. MRCKα Is Co-Amplified with the Oncogenes AKT3 and ARID4B in Breast Cancer
In cancer, some genes are amplified not because they are driver genes themselves but
because they are co-amplified with an oncogene in the vicinity. We therefore, tested in
breast cancers of the TCGA PanCancer dataset whether other amplified oncogenes are close
to the chromosomal location of the MRCKα gene (Chr 1q41.13). Indeed, both ARID4B (Chr
1q42.3) and AKT3 (Chr 1q43-q44) are in the neighborhood of the MRCKα gene. ARID4B is
an activator of the PI3K-AKT pathway, an oncogene in PTEN-deficient prostate cancer [25]
and amplified in 12% of breast cancers in the TCGA data set. AKT3 showed an oncogenic
effect in the murine MMTV-PymT mammary cancer model [26]. Around 11% of human
breast cancers show amplification of AKT3. Interestingly, ARID4B, MRCKα and AKT3 are
mostly amplified together and show a highly significant co-occurrence of genetic alterations
in breast cancer (Figure 9a,b).
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Figure 9. MRCKα is co-amplified with ARID4B and AKT3. (a) Oncoprints of genomic alterations
of MRCKα, ARID4B and AKT3 in human breast cancers. (b) Analysis of co-occurrence of MRCKα
with the oncogenes ARID4B and AKT3. All analyses were generated in cBioportal (TCGA PanCancer
Atlas, breast cancer samples, accessed on 20 February 2021).
Importantly, patients with amplified ARID4B showed a significant decrease in disease-
free survival (p = 0.049), in contrast to patients with amplified MRCKα (p = 0.101) and AKT3
(p = 0.108), despite the high overlap of the patient populations. Cancer with amplified
ARID4B displayed a 29% increase in ARID4B expression, which was highly significant
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(1.17 × 10−8). AKT3 expression was similarly increased in cancers with AKT3 amplifica-
tion, but with a much lower significance (28%; p = 0.036). Compared to amplifications of
MRCKα and AKT3, amplifications of ARID4B showed the strongest enrichment in the
Basal cancer subtype.
These statistical analyses of patient data suggest that ARID4B might have the strongest
tumor promoting effect of the three co-amplified genes. Furthermore, the correlation of
MRCKα expression with breast cancer formation and progression appears to be at least
partly due to the co-amplification with AKT3 and in particular ARID4B.
4. Discussion
In order to study MRCKα function in breast cancer, we first established mice with a
constitutive inactivation of the MRCKα gene in all cells. Previous in vitro studies suggested
a role for MRCKα in developmental processes involving Cdc42 dependent cell migration
and in neurite formation in the brain [12,27]. Analysis of our MRCKα KO mice did not
reveal an obvious developmental function, which might be caused by redundant function
of the closely related MRCKβ gene.
Despite the genetic amplification of MRCKα in human breast cancers, we found that
loss of MRCKα had no obvious effect on primary tumor growth in the murine MMTV-
PyMT model. Since inhibition of MRCKα and MRCKβ decreased papilloma volume in a
DMBA/TPA induced skin tumor model [4], functional redundancy between MRCKα and
MRCKβ or tumor specific function could explain the normal growth of MRCKα KO breast
cancers. Cell-type specific effect of MRCKs were already observed earlier when testing
757 cancer cell lines from 45 different tumors for their sensitivity to MRCK inhibitors [4].
Here, hematopoietic cancers showed growth inhibition at much lower doses than breast
cancer cell lines. In this context, it should be noted that acute inhibition by small molecule
inhibitors might result in different effects than chronic elimination of a protein, which could
trigger compensatory mechanisms [28]. We tested for a compensatory effect of ROCK in
4T1 cells lacking MRCKα and MRCKβ by treatment with the ROCK inhibitor Y27632, but
did not observe it in this cell line.
MDA-MB-231 and 4T1 are triple negative breast cancer cell lines, which is similar to
the Basal breast cell cancer subtype. The MMTV-PyMT breast cancer corresponds to the
human Luminal B subtype [23]. However, more extensive experiments are required to test
whether the findings can be extrapolated to all breast cancer subtypes.
An alternative explanation for the reported results is that MRCKα is a passenger
gene that is co-amplified with ARID4B and AKT3, which have been reported to be driver
genes in earlier studies, although no clinical studies have been carried out investigating
their prognostic value. High expression of MRCKα could therefore correlate with a bad
prognosis, although MRCKα itself might not be an oncogene.
Based on earlier studies, a role for MRCKα was expected in invasion and metastasis of
breast cancer cells. Previously, it was shown that siRNA mediated inhibition of MRCKα and
MRCKβ in cancer cells reduced their invasion into collagen gel [10]. Similarly, simultaneous
knockdown of MRCKα and MRCKβ in MDA-MB-231 cells decreased their invasion into
matrigel [9]. Moreover, collective migration of squamous cell carcinoma cells SSC12 in an
organotypic culture system including fibroblasts was strongly reduced after knockdown
of MRCKα and MRCKβ [11]. In human breast cancer, MRCKα is amplified in many
patients, correlating with early metastasis [13]. Indeed, we found that deleting the MRCKα
gene either alone or together with MRCKβ significantly reduced 3D collagen invasion
of MDA-MB-231 cells. This altered invasion in 3D did not correlate with changes in
pMLC or pCofilin in 2D culture, indicating either a different regulation of cell contraction
(pMLC) and F-actin severing (pCofilin) in 3D vs. 2D or a different mechanism for MRCKα
dependent invasion of MDA-MB-231 cells.
In the MMTV-PyMT breast cancer model, however, no significant reduction of lung
metastases was observed in the absence of MRCKα. In contrast to MDA-MB-231 cells, can-
cer cells of the MMTV-PyMT model showed collective migration in collagen as tested with
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tumor organoids, suggesting that the mode of migration might determine the importance
of MRCKα in breast cancer. This notion is supported by the finding that MRCKα is not
required for the 3D collagen invasion of the murine 4T1 breast cancer cell line, which also
shows collective migration. Whether species specific differences contribute to the observed
changes could not be determined.
Using a murine knockout model, the current study reveals that MRCKα is not essential
for PyMT induced breast cancer. However, our results do not exclude that increased
expression of MRCKα could promote breast cancer or exacerbate its progression.
Taken together, these data support further analysis of MRCKα expression as a possible
prognostic marker, but do not validate MRCKα as a drug target in breast cancer, although
it might play a role in a subset of cancers showing mesenchymal migration.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/cells10040942/s1. Supplementary legends. Figure S1: (a) Overall survival of breast cancer
patients with high and low expression of MRCKβ (p = 0.899). (e) Breast cancer subtype distribution of
patients with high and low expression of MRCKβ. Graphs were generated in cBioPortal.org using the
TCGA PanCancer Atlas data set for invasive breast carcinoma (accessed on 20 March 2021). Figure S2:
MRCKα knockout tumour organoids metastasize normally, Figure S3. RNA-seq analysis of MRCKα
knockout cells, Figure S4. RNA-seq analysis of MRCKβ knockout cells, Figure S5. RNA-seq analysis
of MRCK DKO cell, Figure S6. MRCKα knockout in 4T1 cells results in MRCKβ up-regulation, Video
S1: Invasion of control MDA-MB-231 breast cancer cells into 3D collagen gel, Video S2: Invasion of
MRCKα/MRCKβ DKO MDA-MB-231 breast cancer cells into 3D collagen gel.
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